A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

Palbociclib is a CDK4/6 inhibitor that received FDA approval for treatment of hormone receptor positive (HR+) HER2 negative (HER2neg) advanced breast cancer. To better personalize patients treatment it is critical to identify subgroups that would mostly benefit from it. We hypothesize that complex a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Malorni, Luca, Piazza, Silvano, Ciani, Yari, Guarducci, Cristina, Bonechi, Martina, Biagioni, Chiara, Hart, Christopher D., Verardo, Roberto, Leo, Angelo Di, Migliaccio, Ilenia
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356535/
https://ncbi.nlm.nih.gov/pubmed/27634906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados